TABLE 2.

Characteristics of human clinical studies.

Study	Study types	Intervention	Control	Epilepsy types	Intervention group/Control group	Age (mean ± SD or range)	Gender (M/F)	Treatment time
Wu et al., 2002	Clinical trial	Modified formula of Chaihu-longu-muli-tang (TW970) (8 mg/day)	None	Partial epilepsy	I: group A: 20 refractory epilepsy; group B: 20 benign epilepsy C: group C: 20 age-matched healthy adults	A: 25.9 ± 7.0 B: 27.5 ± 10.0	A:11/9 B: 9/11	4 m
Ma et al., 2003	Observational study	Anti-epilepsy capsules (≤5 years old: 1–5 capsules 6–10 years old: 7 capsules 11–14 years old: 8 capsules for each time, three times daily)	Luminal (1.5–2 mg/kg each time, three times daily)	Generalized and partial epilepsy	930/160	1–14	I: 518/412 C: 95/65	6 m
He et al., 2011	Randomized and controlled multicenter clinical trial	Dianxianning pills (four pills three times daily)	Placebo pills (four pills three times daily)	Generalized tonic-clonic seizures or partial seizure	141/71	I: 33.99 ± 15.05 C: 33.90 ± 16.30	I: 87/50 C: 41/28	3 m
Wang et al., 2018	Observational study	Ganoderma lucidum spore powder (three times daily)	None	Systemic, partial, and atypical attack of seizure	18/none	39.4 ± 15.3	10/8	8 w

SD, standard deviation; I, intervention; C, control; m, months; w, weeks.